BACKGROUND: PR-104 is rapidly hydrolyzed to PR-104A in vivo, which is activated by reduction to the corresponding 5-hydroxylamine (PR-104H) and amine (PR-104M) to produce DNA interstrand cross-links. PR-104 activation can occur via hypoxia-dependent reductases and also independently of hypoxia by aldo-keto reductase (AKR) 1C3. PROCEDURES: PR-104A was tested against the PPTP in vitro panel (10 nM to 100 µM), and PR-104 in vivo using a weekly × 6 schedule at its maximum tolerated dose (MTD) of 550 mg/kg. Subsequently PR-104 was tested at 270 and 110 mg/kg. Pharmacokinetics for PR-104 and its metabolites were determined, as were levels of AKR1C3 RNA and protein in xenografts. RESULTS: In vitro, the leukemia models were most sensitive to PR-104A. In vivo, PR-104 induced objective responses at its MTD in 21/34 solid tumor models and maintained complete responses against 7/7 acute lymphoblastic leukemia (ALL) models. At 270 mg/kg and lower dose levels, PR-104 did not induce solid tumor regressions, suggesting a steep dose-response relationship. Pharmacokinetic analysis suggests higher systemic exposures to PR-104A and its metabolites in mice compared to those achievable in patients. Levels of AKR1C3 protein did not correlate with tumor responsiveness. CONCLUSIONS: As monotherapy, PR-104 demonstrated a high level of activity against both solid tumor and ALL models at its MTD, but the activity was almost completely lost at half the MTD dose for solid tumors. Pharmacokinetic data at the PR-104 MTD from human trials suggest that PR-104 metabolites may not reach the plasma exposures in children that were associated with high-level preclinical activity.
BACKGROUND:PR-104 is rapidly hydrolyzed to PR-104A in vivo, which is activated by reduction to the corresponding 5-hydroxylamine (PR-104H) and amine (PR-104M) to produce DNA interstrand cross-links. PR-104 activation can occur via hypoxia-dependent reductases and also independently of hypoxia by aldo-keto reductase (AKR) 1C3. PROCEDURES: PR-104A was tested against the PPTP in vitro panel (10 nM to 100 µM), and PR-104 in vivo using a weekly × 6 schedule at its maximum tolerated dose (MTD) of 550 mg/kg. Subsequently PR-104 was tested at 270 and 110 mg/kg. Pharmacokinetics for PR-104 and its metabolites were determined, as were levels of AKR1C3 RNA and protein in xenografts. RESULTS: In vitro, the leukemia models were most sensitive to PR-104A. In vivo, PR-104 induced objective responses at its MTD in 21/34 solid tumor models and maintained complete responses against 7/7 acute lymphoblastic leukemia (ALL) models. At 270 mg/kg and lower dose levels, PR-104 did not induce solid tumor regressions, suggesting a steep dose-response relationship. Pharmacokinetic analysis suggests higher systemic exposures to PR-104A and its metabolites in mice compared to those achievable in patients. Levels of AKR1C3protein did not correlate withtumor responsiveness. CONCLUSIONS: As monotherapy, PR-104 demonstrated a high level of activity against bothsolid tumor and ALL models at its MTD, but the activity was almost completely lost at half the MTD dose for solid tumors. Pharmacokinetic data at the PR-104 MTD from human trials suggest that PR-104 metabolites may not reach the plasma exposures in childrenthat were associated with high-level preclinical activity.
Authors: Markos Leggas; Clinton F Stewart; Michael H Woo; Maryam Fouladi; Pamela J Cheshire; Jennifer K Peterson; Henry S Friedman; Catherine Billups; Peter J Houghton Journal: Clin Cancer Res Date: 2002-09 Impact factor: 12.531
Authors: M E Horowitz; E Etcubanas; M L Christensen; J A Houghton; S L George; A A Green; P J Houghton Journal: J Clin Oncol Date: 1988-02 Impact factor: 44.544
Authors: Natalia L M Liem; Rachael A Papa; Christopher G Milross; Michael A Schmid; Mayamin Tajbakhsh; Seoyeon Choi; Carole D Ramirez; Alison M Rice; Michelle Haber; Murray D Norris; Karen L MacKenzie; Richard B Lock Journal: Blood Date: 2004-02-05 Impact factor: 22.113
Authors: H S Friedman; O M Colvin; S X Skapek; S M Ludeman; G B Elion; S C Schold; P F Jacobsen; L H Muhlbaier; D D Bigner Journal: Cancer Res Date: 1988-08-01 Impact factor: 12.701
Authors: Nathan Lawrentschuk; Fook T Lee; Gareth Jones; Angela Rigopoulos; Angela Mountain; Graeme O'Keefe; Anthony T Papenfuss; Damien M Bolton; Ian D Davis; Andrew M Scott Journal: Urol Oncol Date: 2009-06-12 Impact factor: 3.498
Authors: Donya Moradi Manesh; Jad El-Hoss; Kathryn Evans; Jennifer Richmond; Cara E Toscan; Lauryn S Bracken; Ashlee Hedrick; Rosemary Sutton; Glenn M Marshall; William R Wilson; Raushan T Kurmasheva; Catherine Billups; Peter J Houghton; Malcolm A Smith; Hernan Carol; Richard B Lock Journal: Blood Date: 2015-06-26 Impact factor: 22.113
Authors: Juliana Benito; Yuexi Shi; Barbara Szymanska; Hernan Carol; Ingrid Boehm; Hongbo Lu; Sergej Konoplev; Wendy Fang; Patrick A Zweidler-McKay; Dario Campana; Gautam Borthakur; Carlos Bueso-Ramos; Elizabeth Shpall; Deborah A Thomas; Craig T Jordan; Hagop Kantarjian; William R Wilson; Richard Lock; Michael Andreeff; Marina Konopleva Journal: PLoS One Date: 2011-08-11 Impact factor: 3.240
Authors: Kathryn Evans; JianXin Duan; Tara Pritchard; Connor D Jones; Lisa McDermott; Zhaohui Gu; Cara E Toscan; Narimanne El-Zein; Chelsea Mayoh; Stephen W Erickson; Yuelong Guo; Fanying Meng; Donald Jung; Komal S Rathi; Kathryn G Roberts; Charles G Mullighan; Chi-Sheng Shia; Tillman Pearce; Beverly A Teicher; Malcolm A Smith; Richard B Lock Journal: Clin Cancer Res Date: 2019-04-23 Impact factor: 13.801
Authors: F Khanim; N Davies; P Veliça; R Hayden; J Ride; C Pararasa; M G Chong; U Gunther; N Veerapen; P Winn; R Farmer; E Trivier; L Rigoreau; M Drayson; C Bunce Journal: Br J Cancer Date: 2014-02-25 Impact factor: 7.640
Authors: Annika Foehrenbacher; Kashyap Patel; Maria R Abbattista; Chris P Guise; Timothy W Secomb; William R Wilson; Kevin O Hicks Journal: Front Oncol Date: 2013-10-07 Impact factor: 6.244